POCARED Diagnostics

Automated, Reagent-free Microorganism Detection

Health Tech & Life Sciences
Non Active, Feb 2025 ceased to operate

Company Overview

Snapshot

Founded in July 2004 by Jonathan Gurfinkel and Gal Ingber, POCARED Diagnostics operated with 1–10 employees. The company secured funding across 5 rounds from 6 investors. In May 2022, the European Investment Bank (EIB) provided backing for the completion of development and commercialization of its rapid testing system.

Business overview

POCARED Diagnostics is an in vitro diagnostics company focused on developing a microbiology platform. Its core technology, the P-1000 system, utilizes intrinsic fluorescence, optical data analysis, and artificial intelligence to analyze the multidimensional optical characteristics of microorganisms, enabling rapid detection of pathogens. Additionally, POCARED's SP is a rapid-filtration-based fractionation concentration platform designed for efficient concentration of biological particles and high cell recovery. The company operates in the Health Tech & Life Sciences sector, serving global markets with its diagnostic solutions for laboratories and hospitals.

Strategic signal

In May 2022, POCARED Diagnostics secured backing from the European Investment Bank (EIB) to complete the development and commercialization of its rapid infectious diseases testing system. This investment signals a critical validation of the company's technology and its potential to address urgent needs in rapid diagnostics, positioning it for market entry and broader adoption in the healthcare industry.

Company Intelligence Q&A

What is the current status of POCARED Diagnostics?
POCARED Diagnostics is currently non-active, having ceased operations in February 2025.
When was POCARED Diagnostics founded and by whom?
POCARED Diagnostics was founded in July 2004 by Jonathan Gurfinkel and Gal Ingber.
What was a significant funding event for POCARED Diagnostics?
In May 2022, POCARED Diagnostics secured backing from the European Investment Bank (EIB) for the completion of development and commercialization of its rapid testing system.
Which investor committed capital to POCARED Diagnostics in July 2021?
In July 2021, POCARED Diagnostics secured a capital commitment from Global Emerging Markets Group (GEM) as the company considered going public via a SPAC merger.
What was the nature of the funding round in March 2014?
In March 2014, POCARED Diagnostics received funding from RDC and Elron Ventures.

External links